JA1 Technical Report – WP1: Appendix 1
This document is Appendix 1 for WP1 under the JA1 Final Technical Report: “WP1/Exec Comm f-t-f meeting summary, April 18-19, 2012, Rome, Italy” Please note that within this appendix, you will find references to its own set of 9 annexes. These are all included in the document attached below. NOTE: For the full Technical Report, please follow […]
EMA-EUnetHTA press release on joint 3-year work plan
EMA-EUnetHTA press release on 3-year work plan
EMA-EUnetHTA 3-year Work Plan
This document is the 3-year work plan between the European Medicines Agency (EMA) and EUnetHTA. EMA-EUnetHTA three year work plan – final version
EUnetHTA JA1 Final Technical Report
This report is the Final Technical Report on the Implementation of the European network for Health Technology Assessment Joint Action 1 (2010-2012) delivered by the Co-ordinator, the Danish Health and Medicines Authority (DHMA) to the Executive Agency for Health and Consumers (EAHC). Please find the full final JA1 Technical Report attached at the bottom of this page. Please […]
Abdominal Aorta Aneurysm Screening (AAA)
Abdominal aortic aneurysm (AAA) is a pathological focal dilatation of the abdominal stem artery. AAA rupture is a dramatic emergency condition with a high risk of death. The editors of this joint assessment are Agenas, Italy and NOKC, Norway and the editorial team consists of LBI-HTA, Austria; GÖG, Austria, ISCIII-AETS, Spain; NOKC, Norway; THL-FINOHTA, Finland, […]
A new application of the HTA Core Model – the HTA Core Model for Rapid Relative Effectiveness Assessment of pharmaceuticals
The HTA Core Model defines the content elements to be considered in a health technology assessment (HTA) and facilitates standardised reporting. The aim is to share information, to avoid duplication of work, and to facilitate the adaptation of information in national HTA reports and the co-production of HTA reports (by multiple HTA agencies). Detailed information […]
1st pilot rapid assessment of WP5 JA2 Strand B on “Duodenal-jejunal bypass sleeve for the treatment of obesity with or without Type II Diabetes Mellitus”
The purpose of the assessment is to examine the effectiveness and safety of the duodenal-jejunal bypass sleeve/EndoBarrier® in in adults aged 18 years or older with grade II or III obesity (with comorbidities) and/or type 2 diabetes mellitus (+ obesity ≥ grade I) who are not adequately controlled with medication (oral and/or insulin) and lifestyle […]
Methodological guideline for REA of pharmaceuticals: Direct and indirect comparison
To make the best use of available evidence on the efficacy of a treatment, it is common to combine results from several randomised controlled trials (RCTs) in a meta-analysis. This guideline focuses on the methods available for treatment comparisons. Their strengths and limitations are discussed and recommendations are provided in order to support Relative Effectiveness […]
Methodological guideline for REA of pharmaceuticals: Criteria for the choice of the most appropriate comparator(s)
This document provides a summary of current national policies and best practice recommendations for HTA assessors for selecting the most appropriate comparator for relative effectiveness assessments. The comparator in a relative effectiveness assessment (REA) is a health care intervention or other technology with which a pharmaceutical is compared in order to establish if it has […]
Methodological guideline for REA of pharmaceuticals: Health-related quality of life
This guideline provides a set of recommendations for the selection and assessment of Health-related quality of life (HRQoL) when completing a Relative Effectiveness Assessment (REA) of pharmaceuticals. Health-related quality of life (HRQoL) is often considered to be an important endpoint of health care interventions. Because improvement in HRQoL is highly subjective, it does not necessarily […]
